Why is Saudi Arabia investing so heavily in biotechnology?
Biotechnology is central to Vision 2030's drive to diversify the Saudi economy beyond oil. The National Biotechnology Strategy targets a $34.6bn contribution to non-oil GDP by 2040, built on four pillars: vaccines, biomanufacturing, genomics and plant optimisation. Alongside economic diversification, the aim is to localise healthcare and pharmaceutical manufacturing, build sovereign precision-medicine and genomics capability, and strengthen food security. Saudi Arabia is the largest of several Gulf biotech programmes, with the UAE and Qatar advancing national strategies of their own. A7i Intelligence tracks each mandate, tender and investment across the GCC as it moves.
What are the biggest biotechnology opportunities in the Gulf?
The clearest openings are in pharmaceutical manufacturing and localisation, diagnostics and medical devices, precision medicine and genomics, digital and AI-enabled health, and wellness and functional food, across Saudi Arabia, the UAE and Qatar. Saudi localisation mandates open named partner slots for international manufacturers willing to transfer technology, as seen in Lifera's CDMO agreements with Novo Nordisk, Pfizer and Jamjoom Pharma. For companies with the right product and the willingness to commit, the window is open now rather than in a decade.
Where can I find reliable news on Gulf biotechnology and healthcare?
A7i Intelligence reports on government mandates, capital flows, regulatory developments, manufacturing, partnerships and emerging companies across the GCC. The Wire feed carries developments as they happen, tagged by regulatory, market, partnership and opportunity. The weekly newsletter reads those developments for what each one opens up for the companies positioned to act.
What is the Saudi National Biotechnology Strategy?
It is the Kingdom's plan to build a biotech economy around four pillars: vaccines and biomanufacturing, localisation of manufacturing, genomics and precision medicine, and plant optimisation for food security. It targets a $34.6bn contribution to non-oil GDP by 2040 and underpins much of the localisation, manufacturing and research activity now moving across Saudi Arabia. It is the most developed of the Gulf's national biotech plans, with the UAE and Qatar advancing their own.
How does a foreign biotech or medtech company enter the Saudi or wider Gulf market?
A foreign manufacturer without a Saudi legal entity must appoint an SFDA authorised representative to hold its product registrations and act as the regulatory point of contact inside the Kingdom. From there, market entry runs through product registration, distribution appointment and access to government and institutional buyers. Each other GCC market runs through its own regulator and route. A7i Partners acts as the operating partner across that path, from the regulatory file through to the route to market.
What is the SFDA and why does it matter for market entry?
The Saudi Food and Drug Authority regulates medicines, medical devices, food and supplements in the Kingdom. It sets the registration and evidence requirements every product must meet before it can be sold, including a defined approval pathway for AI-enabled medical devices under its MDS-G53 guidance. No medical or wellness product reaches the Saudi market without clearing the SFDA first, which makes early regulatory planning decisive.
Who is funding longevity and aging research in the Gulf?
The Hevolution Foundation, based in Riyadh, has committed more than $400m to aging and healthspan research and backs the $101m XPRIZE Healthspan, the largest longevity prize to date. It is one of the most active funders of healthspan science globally, and its presence has helped position Riyadh as a hub for longevity research and investment.
Does A7i Intelligence have a podcast?
Yes. The Gulf Biotech Brief brings operators, regulators and founders building Gulf health into long-form conversation. Season one is recording now, launching on Spotify, Apple Podcasts and YouTube, and hosted on the A7i Intelligence site.
Weighing Gulf entry?
A7i Partners takes international biotech and medtech into the Kingdom as your operating partner on the ground. A7i Wellness places wellness and functional food brands across Saudi retail, pharmacy and hospitality.